Holen Sie sich die Stockscreener-App
3.77
1.89%
0.07
Handel nachbörslich:
4.21
0.44
+11.67%
Macrogenics Inc Aktie (MGNX) Neueste Nachrichten
MacroGenics: Q3 Earnings Snapshot - San Antonio Express-News
MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results - The Manila Times
Macrogenics Earnings Preview - Benzinga
Earnings To Watch: Macrogenics Inc (MGNX) Reports Q3 2024 Result - GuruFocus.com
MacroGenics (NASDAQ:MGNX) Lowered to Sell Rating by StockNews.com - MarketBeat
MacroGenics CEO Scott Koenig to resign early next year - Investing.com India
MacroGenics Announces Leadership Transition - GlobeNewswire
MacroGenics (MGNX) Scheduled to Post Earnings on Tuesday - MarketBeat
MacroGenics Co-Founder Koenig Stepping Down as President, CEO - MarketWatch
MacroGenics CEO Scott Koenig to resign early next year By Investing.com - Investing.com UK
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call - GlobeNewswire
MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Rating of "Hold" from Analysts - MarketBeat
MacroGenics (NASDAQ:MGNX) Stock Rating Upgraded by StockNews.com - MarketBeat
Rigrodsky Law, P.A. Is Investigating MacroGenics, Inc. On Behalf of Shareholders - StockTitan
MacroGenics' SWOT analysis: stock faces challenges amid pipeline setbacks - Investing.com India
Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and MaplebearJohnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information - GlobeNewswire
MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA - citybiz
MGNXMacroGenics, Inc. Latest Stock News & Market Updates - StockTitan
MacroGenics sells breast cancer treatment to TerSera - The Business Journals
TerSera acquires rights to MacroGenics cancer drug MARGENZA - Investing.com
MacroGenics to Sell Margenza Cancer Drug for $40 Million - MarketWatch
MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA® - Business Wire
TerSera Therapeutics LLC has entered into an agreement to acquire MARGENZA® from MacroGenics, Inc. for $75 million. - Marketscreener.com
Prepare Yourself for Liftoff: Macrogenics Inc (MGNX) - SETE News
Investor’s Delight: Macrogenics Inc (MGNX) Closes Weak at 3.98, Down -7.01 - The Dwinnex
What was Macrogenics Inc (MGNX)’s performance in the last session? - US Post News
The MGNX Stock Puzzle: Unraveling Macrogenics Inc’s Fluctuating Performance - The InvestChronicle
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DXC, - EIN News
Examining Macrogenics Inc (MGNX) stock is warranted - US Post News
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc.MGNX - cnhinews.com
Dimensional Fund Advisors LP Reduces Stock Position in MacroGenics, Inc. (NASDAQ:MGNX) - MarketBeat
Innovative B7-H3 Inhibitors Set to Transform Cancer Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Millennium Management LLC Boosts Stock Position in MacroGenics, Inc. (NASDAQ:MGNX) - MarketBeat
MacroGenics, Inc. (NASDAQ:MGNX) Position Increased by Marshall Wace LLP - MarketBeat
Macrogenics Inc [MGNX] Senior VP and General Counsel makes an insider purchase of 51,395 shares worth 0.8 million. – Knox Daily - Knox Daily
Renaissance Technologies LLC Sells 231,000 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - MarketBeat
Perhaps timely catching Macrogenics Inc (MGNX) would be a good idea - SETE News
The Macrogenics Inc (MGNX) had a good session last reading, didn’t it? - US Post News
Macrogenics Inc (MGNX)’s Market Momentum: Closing Strong at 3.19, Up 4.93 - The Dwinnex
MacroGenics' SWOT analysis: vobra-duo safety concerns weigh on stock outlook - Investing.com
MacroGenics' SWOT analysis: vobra-duo safety concerns weigh on stock outlook By Investing.com - Investing.com South Africa
Recent Insider Activity Suggests Potential Gains for Macrogenics Inc (MGNX) - Knox Daily
Frazier Life Sciences Management L.P. Has $12.80 Million Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - MarketBeat
Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely - Yahoo Finance
Armistice Capital LLC Purchases 3,600,000 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - MarketBeat
Take off with Macrogenics Inc (MGNX): Get ready for trading - SETE News
DRW Securities LLC Takes $56,000 Position in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Investors in MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your RightsMGNX - PR Newswire
Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – MGNX - AccessWire
Versant Venture sells $7.4m in Monte Rosa Therapeutics stock By Investing.com - Investing.com Canada
Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024MGNX - AccessWire
Class Action Filed Against MacroGenics, Inc. (MGNX) Seeking Recovery for InvestorsContact Levi & Korsinsky - AccessWire
Shareholders of MacroGenics, Inc. Should Contact The Gross - GlobeNewswire
Macrogenics Inc (MGNX) may enjoy gains as insiders got busy in the recent days - Knox Daily
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):